Recognized for innovation with the COVID-19 vaccine, the company has been shortlisted for the Best New Vaccine Technology/Platform Award for the 17th Annual ViE Awards 2024 at the prestigious World Vaccine Congress Washington. 

Led by visionary founder Dr. Jia-Ming Chang, Vacino’s proprietary Vacino-BT brain delivery platform is making waves in biotech. This cutting-edge platform enables targeted drug delivery across the blood-brain barrier (BBB), setting the stage for transformative treatments.

The star of the show? Vacino-ADmir, a miRNA therapy designed to combat Alzheimer’s at its root. Unlike traditional treatments focusing only on symptoms, this therapy tackles neuroinflammation via the PD1/PDL1 pathway, offering a groundbreaking approach to dementia and related diseases.

With top pharma giants lining up for partnerships, Vacino is spearheading the next wave of nucleic acid therapeutics—poised to dominate the industry’s golden era in the coming years.

Join the journey of innovation!

Read more: Vacino’s Story
https://news.gbimonthly.com/tw/magazine/article_show.php?num=73119

Follow #GlobalBio vol. 122 for the latest RNA breakthroughs!

#Alzheimers #BiotechInnovation #miRNATherapy #BrainHealth #NucleicAcidDrugs #WorldVaccineCongress #VacinoBiotech